$BPMC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Blueprint Medicines Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Blueprint Medicines Corp. Get notifications about new insider transactions in Blueprint Medicines Corp for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 05 2019 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Option Exercise | A | 0.00 | 8,050 | 0 | 8,050 | |
| Mar 05 2019 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Option Exercise | A | 86.60 | 29,900 | 2,589,340 | 29,900 | |
| Mar 05 2019 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | A | 0.00 | 29,750 | 0 | 29,750 | |
| Mar 05 2019 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | A | 86.60 | 110,500 | 9,569,300 | 110,500 | |
| Nov 21 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 28,961 | 54,157 | 886,073 | |
| Nov 21 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 28,961 | 54,157 | 28,961 | 0 to 29 K |
| Nov 07 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 20,000 | 37,400 | 915,034 | |
| Nov 07 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 62.66 | 100 | 6,266 | 0 | 100 to 0 (-100.00 %) |
| Nov 07 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 63.30 | 17,300 | 1,095,090 | 100 | 17.4 K to 100 (-99.43 %) |
| Nov 07 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 64.18 | 1,500 | 96,270 | 17,400 | 18.9 K to 17.4 K (-7.94 %) |
| Nov 07 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 65.53 | 1,100 | 72,083 | 18,900 | 20 K to 18.9 K (-5.50 %) |
| Nov 07 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 20,000 | 37,400 | 20,000 | 0 to 20 K |
| Nov 05 2018 | BPMC | Blueprint Medicine ... | Rossi Christina | Chief Commercial Of ... | Option Exercise | A | 0.00 | 4,500 | 0 | 4,500 | |
| Nov 05 2018 | BPMC | Blueprint Medicine ... | Rossi Christina | Chief Commercial Of ... | Option Exercise | A | 65.75 | 80,000 | 5,260,000 | 80,000 | |
| Sep 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Option Exercise | M | 37.11 | 2,300 | 85,353 | 116,900 | |
| Sep 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 70.00 | 1,700 | 119,000 | 0 | 1.7 K to 0 (-100.00 %) |
| Sep 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 70.59 | 300 | 21,177 | 1,700 | 2 K to 1.7 K (-15.00 %) |
| Sep 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 73.05 | 300 | 21,915 | 2,000 | 2.3 K to 2 K (-13.04 %) |
| Sep 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Buy | M | 37.11 | 2,300 | 85,353 | 2,300 | 0 to 2.3 K |
| Aug 08 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 20,000 | 37,400 | 935,034 | |
| Aug 08 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 68.48 | 802 | 54,921 | 0 | 802 to 0 (-100.00 %) |
| Aug 08 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 69.64 | 800 | 55,712 | 802 | 1.6 K to 802 (-49.94 %) |
| Aug 08 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 70.48 | 12,219 | 861,195 | 1,602 | 13.8 K to 1.6 K (-88.41 %) |
| Aug 08 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 71.22 | 6,179 | 440,068 | 13,821 | 20 K to 13.8 K (-30.89 %) |
| Aug 08 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 20,000 | 37,400 | 20,000 | 0 to 20 K |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | COATS LONNEL | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 51,136 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | Seely Lynn | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 51,136 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | Rowland Charles A Jr | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 51,136 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | Lydon Nicholas | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 29,318 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | Goldberg Mark Alan | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 51,136 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 64,771 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | Borisy Alexis | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 29,318 | |
| Jun 25 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 29,318 | |
| May 09 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 20,000 | 37,400 | 955,034 | |
| May 09 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 78.56 | 8,320 | 653,619 | 0 | 8.3 K to 0 (-100.00 %) |
| May 09 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 79.15 | 11,680 | 924,472 | 8,320 | 20 K to 8.3 K (-58.40 %) |
| May 09 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 20,000 | 37,400 | 20,000 | 0 to 20 K |
| Mar 21 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 99.06 | 1,200 | 118,872 | 6,439 | 7.6 K to 6.4 K (-15.71 %) |
| Mar 21 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 100.04 | 2,592 | 259,304 | 7,639 | 10.2 K to 7.6 K (-25.33 %) |
| Mar 21 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 100.88 | 1,700 | 171,496 | 10,231 | 11.9 K to 10.2 K (-14.25 %) |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 36.05 | 2,500 | 90,125 | 118,139 | |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 16.28 | 1,571 | 25,576 | 120,639 | |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 99.20 | 571 | 56,643 | 5,874 | 6.4 K to 5.9 K (-8.86 %) |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 100.02 | 1,200 | 120,024 | 6,445 | 7.6 K to 6.4 K (-15.70 %) |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 101.32 | 1,800 | 182,376 | 7,645 | 9.4 K to 7.6 K (-19.06 %) |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 102.19 | 500 | 51,095 | 9,445 | 9.9 K to 9.4 K (-5.03 %) |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 36.05 | 2,500 | 90,125 | 9,945 | 7.4 K to 9.9 K (+33.58 %) |
| Mar 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 16.28 | 1,571 | 25,576 | 7,445 | 5.9 K to 7.4 K (+26.74 %) |
| Mar 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Option Exercise | M | 37.11 | 2,300 | 85,353 | 119,200 | |
| Mar 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 100.07 | 2,300 | 230,161 | 0 | 2.3 K to 0 (-100.00 %) |
| Mar 19 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Buy | M | 37.11 | 2,300 | 85,353 | 2,300 | 0 to 2.3 K |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 20,000 | 37,400 | 975,034 | |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 88.17 | 1,300 | 114,621 | 0 | 1.3 K to 0 (-100.00 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 89.07 | 2,284 | 203,436 | 1,300 | 3.6 K to 1.3 K (-63.73 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 90.52 | 600 | 54,312 | 3,584 | 4.2 K to 3.6 K (-14.34 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 91.66 | 4,100 | 375,806 | 4,184 | 8.3 K to 4.2 K (-49.49 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 92.76 | 1,900 | 176,244 | 8,284 | 10.2 K to 8.3 K (-18.66 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 93.89 | 3,794 | 356,219 | 10,184 | 14 K to 10.2 K (-27.14 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 94.79 | 6,022 | 570,825 | 13,978 | 20 K to 14 K (-30.11 %) |
| Mar 06 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 20,000 | 37,400 | 20,000 | 0 to 20 K |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 36.05 | 3,200 | 115,360 | 125,010 | |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 87.70 | 1,765 | 154,791 | 5,874 | 7.6 K to 5.9 K (-23.11 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 88.32 | 1,035 | 91,411 | 7,639 | 8.7 K to 7.6 K (-11.93 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 89.47 | 200 | 17,894 | 8,674 | 8.9 K to 8.7 K (-2.25 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 90.70 | 200 | 18,140 | 8,874 | 9.1 K to 8.9 K (-2.20 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 36.05 | 3,200 | 115,360 | 9,074 | 5.9 K to 9.1 K (+54.48 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Option Exercise | M | 28.36 | 10,000 | 283,600 | 134,000 | |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Sell | S | 87.69 | 1,106 | 96,985 | 0 | 1.1 K to 0 (-100.00 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Sell | S | 88.40 | 8,794 | 777,390 | 1,106 | 9.9 K to 1.1 K (-88.83 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Sell | S | 90.75 | 100 | 9,075 | 9,900 | 10 K to 9.9 K (-1.00 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Buy | M | 28.36 | 10,000 | 283,600 | 10,000 | 0 to 10 K |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 87.85 | 2,765 | 242,905 | 11,931 | 14.7 K to 11.9 K (-18.81 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 88.45 | 3,085 | 272,868 | 14,696 | 17.8 K to 14.7 K (-17.35 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 89.48 | 200 | 17,896 | 17,781 | 18 K to 17.8 K (-1.11 %) |
| Mar 01 2018 | BPMC | Blueprint Medicine ... | Demetri George | Director | Sell | S | 90.68 | 200 | 18,136 | 17,981 | 18.2 K to 18 K (-1.10 %) |
| Feb 20 2018 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Option Exercise | A | 81.44 | 39,000 | 3,176,160 | 121,500 | |
| Feb 20 2018 | BPMC | Blueprint Medicine ... | McCain Tracey L | EVP and Chief Legal ... | Option Exercise | A | 81.44 | 39,000 | 3,176,160 | 144,000 | |
| Feb 20 2018 | BPMC | Blueprint Medicine ... | Landsittel Michael | PFO and PAO | Option Exercise | A | 81.44 | 26,000 | 2,117,440 | 84,181 | |
| Feb 20 2018 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | A | 81.44 | 39,000 | 3,176,160 | 128,210 | |
| Feb 20 2018 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Option Exercise | A | 81.44 | 39,000 | 3,176,160 | 208,544 | |
| Feb 20 2018 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | A | 81.44 | 170,000 | 13,844,800 | 995,034 | |
| Feb 16 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 80.42 | 12,500 | 1,005,250 | 174,342 | 186.8 K to 174.3 K (-6.69 %) |
| Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 73.27 | 3,996 | 292,787 | 186,842 | 190.8 K to 186.8 K (-2.09 %) |
| Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 74.31 | 3,748 | 278,514 | 190,838 | 194.6 K to 190.8 K (-1.93 %) |
| Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 75.15 | 5,636 | 423,545 | 194,586 | 200.2 K to 194.6 K (-2.81 %) |
| Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 75.96 | 2,590 | 196,736 | 200,222 | 202.8 K to 200.2 K (-1.28 %) |
| Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 77.18 | 1,530 | 118,085 | 202,812 | 204.3 K to 202.8 K (-0.75 %) |
| Nov 24 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Option Exercise | M | 37.11 | 9,166 | 340,150 | 82,500 | |
| Nov 24 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 70.00 | 9,166 | 641,620 | 0 | 9.2 K to 0 (-100.00 %) |
| Nov 24 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Buy | M | 37.11 | 9,166 | 340,150 | 9,166 | 0 to 9.2 K |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Option Exercise | M | 37.11 | 18,334 | 680,375 | 91,666 | |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Buy | S | 64.44 | 500 | 32,220 | 0 | -500 to 0 (-100.00 %) |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 65.16 | 11,483 | 748,232 | 500 | 12 K to 500 (-95.83 %) |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 65.81 | 4,750 | 312,598 | 11,983 | 16.7 K to 12 K (-28.39 %) |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Sell | S | 66.81 | 1,601 | 106,963 | 16,733 | 18.3 K to 16.7 K (-8.73 %) |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Dorsch Marion | Chief Scientific Of ... | Buy | M | 37.11 | 18,334 | 680,375 | 18,334 | 0 to 18.3 K |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 16.28 | 5,874 | 95,629 | 95,985 | |
| Nov 22 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 16.28 | 5,874 | 95,629 | 5,874 | 0 to 5.9 K |
| Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 62.59 | 1,200 | 75,108 | 204,342 | 205.5 K to 204.3 K (-0.58 %) |
| Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 63.25 | 2,200 | 139,150 | 205,542 | 207.7 K to 205.5 K (-1.06 %) |
| Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 64.15 | 1,600 | 102,640 | 207,742 | 209.3 K to 207.7 K (-0.76 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Option Exercise | M | 8.80 | 5,000 | 44,000 | 169,544 | |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 69.59 | 2,380 | 165,624 | 0 | 2.4 K to 0 (-100.00 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 70.29 | 1,520 | 106,841 | 2,380 | 3.9 K to 2.4 K (-38.97 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 71.69 | 700 | 50,183 | 3,900 | 4.6 K to 3.9 K (-15.22 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 72.87 | 200 | 14,574 | 4,600 | 4.8 K to 4.6 K (-4.17 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 74.00 | 200 | 14,800 | 4,800 | 5 K to 4.8 K (-4.00 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Buy | M | 8.80 | 5,000 | 44,000 | 5,000 | 0 to 5 K |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 24,514 | 45,841 | 825,034 | |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 68.95 | 1,100 | 75,845 | 0 | 1.1 K to 0 (-100.00 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 69.74 | 16,469 | 1,148,548 | 1,100 | 17.6 K to 1.1 K (-93.74 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 70.40 | 7,432 | 523,213 | 17,569 | 25 K to 17.6 K (-29.73 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 71.67 | 2,600 | 186,342 | 25,001 | 27.6 K to 25 K (-9.42 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 72.91 | 1,999 | 145,747 | 27,601 | 29.6 K to 27.6 K (-6.75 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 73.89 | 400 | 29,556 | 29,600 | 30 K to 29.6 K (-1.33 %) |
| Nov 08 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 24,514 | 45,841 | 30,000 | 5.5 K to 30 K (+446.85 %) |
| Nov 03 2017 | BPMC | Blueprint Medicine ... | Murray Christopher K. | SVP, Technical Oper ... | Option Exercise | A | 71.80 | 75,000 | 5,385,000 | 75,000 | |
| Oct 10 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 16.28 | 5,449 | 88,710 | 101,859 | |
| Oct 10 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 65.45 | 1,261 | 82,532 | 0 | 1.3 K to 0 (-100.00 %) |
| Oct 10 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 66.58 | 3,303 | 219,914 | 1,261 | 4.6 K to 1.3 K (-72.37 %) |
| Oct 10 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 67.33 | 885 | 59,587 | 4,564 | 5.4 K to 4.6 K (-16.24 %) |
| Oct 10 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 16.28 | 5,449 | 88,710 | 5,449 | 0 to 5.4 K |
| Sep 20 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 16.28 | 6,356 | 103,476 | 107,308 | |
| Sep 20 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 60.03 | 6,356 | 381,551 | 0 | 6.4 K to 0 (-100.00 %) |
| Sep 20 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 16.28 | 6,356 | 103,476 | 6,356 | 0 to 6.4 K |
| Sep 20 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 60.00 | 2,500 | 150,000 | 209,342 | 211.8 K to 209.3 K (-1.18 %) |
| Aug 11 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Option Exercise | M | 8.80 | 5,000 | 44,000 | 174,544 | |
| Aug 11 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 47.79 | 100 | 4,779 | 0 | 100 to 0 (-100.00 %) |
| Aug 11 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 48.21 | 3,085 | 148,728 | 100 | 3.2 K to 100 (-96.86 %) |
| Aug 11 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 49.30 | 1,815 | 89,480 | 3,185 | 5 K to 3.2 K (-36.30 %) |
| Aug 11 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Buy | M | 8.80 | 5,000 | 44,000 | 5,000 | 0 to 5 K |
| Aug 09 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 50.70 | 10,000 | 507,000 | 5,486 | 15.5 K to 5.5 K (-64.57 %) |
| Aug 09 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 48.29 | 2,786 | 134,536 | 15,486 | 18.3 K to 15.5 K (-15.25 %) |
| Aug 09 2017 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 49.21 | 17,214 | 847,101 | 18,272 | 35.5 K to 18.3 K (-48.51 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 55.06 | 7,500 | 412,950 | 211,842 | 219.3 K to 211.8 K (-3.42 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Option Exercise | M | 16.28 | 7,265 | 118,274 | 113,664 | |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 51.54 | 852 | 43,912 | 0 | 852 to 0 (-100.00 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 52.63 | 700 | 36,841 | 852 | 1.6 K to 852 (-45.10 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 53.58 | 700 | 37,506 | 1,552 | 2.3 K to 1.6 K (-31.08 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 54.75 | 700 | 38,325 | 2,252 | 3 K to 2.3 K (-23.71 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Sell | S | 55.76 | 4,313 | 240,493 | 2,952 | 7.3 K to 3 K (-59.37 %) |
| Jul 07 2017 | BPMC | Blueprint Medicine ... | Haviland Kate | Chief Business Offi ... | Buy | M | 16.28 | 7,265 | 118,274 | 7,265 | 0 to 7.3 K |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Option Exercise | M | 8.80 | 10,000 | 88,000 | 179,544 | |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 49.07 | 1,100 | 53,977 | 0 | 1.1 K to 0 (-100.00 %) |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 50.19 | 4,314 | 216,520 | 1,100 | 5.4 K to 1.1 K (-79.68 %) |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Sell | S | 51.08 | 4,586 | 234,253 | 5,414 | 10 K to 5.4 K (-45.86 %) |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | Boral Anthony L. | Chief Medical Offic ... | Buy | M | 8.80 | 10,000 | 88,000 | 10,000 | 0 to 10 K |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 49.09 | 3,125 | 153,406 | 219,342 | 222.5 K to 219.3 K (-1.40 %) |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 50.12 | 21,474 | 1,076,277 | 222,467 | 243.9 K to 222.5 K (-8.80 %) |
| Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 51.17 | 7,901 | 404,294 | 243,941 | 251.8 K to 243.9 K (-3.14 %) |